Model‐informed drug development of autologous CAR‐T cell therapy: Strategies to optimize CAR‐T cell exposure leveraging cell kinetic/dynamic modeling
Abstract Autologous Chimeric antigen receptor (CAR‐T) cell therapy has been highly successful in the treatment of aggressive hematological malignancies and is also being evaluated for the treatment of solid tumors as well as other therapeutic areas. A challenge, however, is that up to 60% of patient...
Main Authors: | Anna M. Mc Laughlin, Peter A. Milligan, Cassian Yee, Martin Bergstrand |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-11-01
|
Series: | CPT: Pharmacometrics & Systems Pharmacology |
Online Access: | https://doi.org/10.1002/psp4.13011 |
Similar Items
-
Letter to the editor: Quality criteria for computational models predicting individual outcomes in CAR-T cell therapy
by: Cassian Yee, et al.
Published: (2023-04-01) -
T Cell Fitness and Autologous CAR T Cell Therapy in Haematologic Malignancy
by: Palak H. Mehta, et al.
Published: (2021-11-01) -
A good response of refractory mantel cell lymphoma to haploidentical CAR T cell therapy after failure of autologous CAR T cell therapy
by: Tongjuan Li, et al.
Published: (2019-02-01) -
Autologous hematopoietic stem cell transplantation for multiple myeloma in the age of CAR T cell therapy
by: Charlotte F. M. Hughes, et al.
Published: (2024-03-01) -
Modeling interaction of Glioma cells and CAR T-cells considering multiple CAR T-cells bindings
by: Runpeng Li, et al.
Published: (2023-03-01)